Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test

▤ Summary

Verici Dx received New York State clinical laboratory approval for its Tutivia kidney transplant rejection test. The approval lets the company offer the test in all 50 U.S. states and the District of Columbia. Tutivia uses transcriptomics and machine learning to help clinicians assess rejection risk, guide biopsy decisions, and manage immunosuppression more precisely. The company positions the approval as both a regulatory milestone and a commercial expansion into nationwide access for transplant centers.

▦ Linked Companies